Theratechnologies Inc.

Universitéde Montreal

Enobia Pharma Inc.

Kiadis Pharma Canada Inc.

Celmed Biosciences Inc.

Denis Gravel

Abdelkrim Habi

Thierry Abribat

Soraya Allas

Andre De Villers

Alcide Chapdelaine

Paul Brazeau

Luc Villeneuve

Hongsheng Su

Marc Vaillancourt

Philippe Crine

Guy Boileau

Isabelle Lemire

Elaref S Ratemi

Mostafa Hatam

Krishna G Peri

Jean Barbeau

Yuan Wang

Jean-Gilles Latour

Serge Beno It

Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2'-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4&#x2032;, 5&#x2032;-dichloro-benzoic acid methyl ester hydrochloride.

Halogenated rhodamine derivatives and applications thereof

The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.

GH secretagogues and uses thereof

Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. Examples of rhodamine compounds include 2'-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4&#x2032;,5&#x2032;-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt 2,7-dibromo-4&#x2032;-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide.

Compounds of formula (I) wherein: one of R1, R2, R3, R4 and (R10)n represents halogen and each remaining R1, R2, R3, R4 and R10 group is independently selected from hydrogen, halogen, amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxy, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio, carboxyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, hydroxysulfonyl, amidosulfonyl, dialkylamidosulfonyl, arylalkylamidosulfonyl, formyl, acyl, aroyl, alkyl, alkylene, alkenyl, aryl, aralkyl, vinyl, alkynyl, and corresponding substituted groups; m=0-1; n=1-4, A is nil, O, or NH; R9 is alkylene; -Z is H, amino, dialkylamino, or a trialkylamino salt; X&#x2212; is an anion; R5, R6, R7 and R8 are independently H or C-Calkyl or R1 in combination with R5 or R6, or R2 in combination with R5 or R6, or R3 in combination with R7 or R8, or R4 in combination with R7 or R8 represents alkylene, are useful alone or with a pharmaceutically acceptable carrier, as intermediates and as bactericides, antiviral agents and in treatment of immunologic disorders.

The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula: 

Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX

The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula:  useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.

Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex

The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1)

Modified GLP-1 peptides with increased biological potency

This invention relates to compositions for removing biofilms from contaminated surfaces. The compositions minimally comprise a detergent and a salt or a salt-forming acid. Preferably, the compositions comprise a detergent and a salt-forming acid, to provide salts and acids in equilibrium, in such a way that the biofilm is rapidly dismantled and removed in such an environment. The compositions may also comprise a bactericide, for destroying bacteria.

Composition for removing biofilms comprising a detergent and a salt forming acid

The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

GRF analogs with increased biological potency

The present invention relates to a long-acting galenical formulation of GRF peptides, GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm,in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.

Long-acting galenical formulation for GRF peptides

Myocardial protection is achieved by administering to a patient an effective amount of a benzothiazepine derivative. The benzothiazepine derivatives have the following general chemical formula: ##STR1## wherein R.sub.1 represents hydrogen or methyl,

Growing community of inventors

Saint-Lambert, Canada

Denis Gravel